Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Anti-CD40-7409 by Protheragen for Non-Small Cell Lung Cancer: Likelihood of Approval
Anti-CD40-7409 is under clinical development by Protheragen and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData,...
Data Insights
Anti-CD40-7409 by Protheragen for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Anti-CD40-7409 is under clinical development by Protheragen and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC)....